» Articles » PMID: 28344581

Type I Interferons As Regulators of Lung Inflammation

Overview
Journal Front Immunol
Date 2017 Mar 28
PMID 28344581
Citations 89
Authors
Affiliations
Soon will be listed here.
Abstract

Immune responses to lung infections must be tightly regulated in order to permit pathogen eradication while maintaining organ function. Exuberant or dysregulated inflammation can impair gas exchange and underlies many instances of lung disease. An important driver of inflammation in the lung is the interferon (IFN) response. Type I IFNs are antiviral cytokines that induce a large range of proteins that impair viral replication in infected cells. This cell-intrinsic action plays a crucial role in protecting the lungs from spread of respiratory viruses. However, type I IFNs have also recently been found to be central to the initiation of lung inflammatory responses, by inducing recruitment and activation of immune cells. This helps control virus burden but can cause detrimental immunopathology and contribute to disease severity. Furthermore, there is now increasing evidence that type I IFNs are not only induced after viral infections but also after infection with bacteria and fungi. The pro-inflammatory function of type I IFNs in the lung opens up the possibility of immune modulation directed against this antiviral cytokine family. In this review, the initiation and signaling of type I IFNs as well as their role in driving and maintaining lung inflammation will be discussed.

Citing Articles

Gene regulatory logic of the interferon-β enhancer contains multiple selectively deployed modes of transcription factor synergy.

Schiffman A, Cheng Z, Ourthiague D, Hoffmann A bioRxiv. 2025; .

PMID: 39975349 PMC: 11838565. DOI: 10.1101/2025.02.04.636520.


Chronic CRYPTOCHROME deficiency enhances cell-intrinsic antiviral defences.

Major-Styles C, Munns J, Zeng A, Vanden Oever M, ONeill J, Edgar R Philos Trans R Soc Lond B Biol Sci. 2025; 380(1918):20230344.

PMID: 39842480 PMC: 11753882. DOI: 10.1098/rstb.2023.0344.


Transcriptomic Biomarkers Associated With Microbiological Etiology and Disease Severity in Childhood Pneumonia.

Williams D, Gautam S, Creech C, Jimenez N, Anderson E, Bosinger S J Infect Dis. 2024; 231(2):e277-e289.

PMID: 39397536 PMC: 11841634. DOI: 10.1093/infdis/jiae491.


Pathogenesis, Diagnosis, and Treatment of Infectious Rhinosinusitis.

Huang F, Liu F, Zhen X, Gong S, Chen W, Song Z Microorganisms. 2024; 12(8).

PMID: 39203531 PMC: 11357447. DOI: 10.3390/microorganisms12081690.


Vaccine and antiviral drug promise for preventing post-acute sequelae of COVID-19, and their combination for its treatment.

Sumi T, Harada K Front Immunol. 2024; 15:1329162.

PMID: 39185419 PMC: 11341427. DOI: 10.3389/fimmu.2024.1329162.


References
1.
Hermesh T, Moltedo B, Moran T, Lopez C . Antiviral instruction of bone marrow leukocytes during respiratory viral infections. Cell Host Microbe. 2010; 7(5):343-53. PMC: 2874206. DOI: 10.1016/j.chom.2010.04.006. View

2.
Goubau D, Schlee M, Deddouche S, Pruijssers A, Zillinger T, Goldeck M . Antiviral immunity via RIG-I-mediated recognition of RNA bearing 5'-diphosphates. Nature. 2014; 514(7522):372-375. PMC: 4201573. DOI: 10.1038/nature13590. View

3.
Berry M, Graham C, McNab F, Xu Z, Bloch S, Oni T . An interferon-inducible neutrophil-driven blood transcriptional signature in human tuberculosis. Nature. 2010; 466(7309):973-7. PMC: 3492754. DOI: 10.1038/nature09247. View

4.
Rouzaut A, Garasa S, Teijeira A, Gonzalez I, Martinez-Forero I, Suarez N . Dendritic cells adhere to and transmigrate across lymphatic endothelium in response to IFN-α. Eur J Immunol. 2010; 40(11):3054-63. DOI: 10.1002/eji.201040523. View

5.
Coccia E, Battistini A . Early IFN type I response: Learning from microbial evasion strategies. Semin Immunol. 2015; 27(2):85-101. PMC: 7129383. DOI: 10.1016/j.smim.2015.03.005. View